| 1 |
吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
|
| 2 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| 3 |
Yotsukura M, Asamura H, Motoi N, et al. Long-term prognosis of patients with resected adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung[J]. J Thorac Oncol, 2021, 16(8): 1312-1320.
|
| 4 |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51.
|
| 5 |
Yang Y, Mao Y, Yang L, et al. Prognostic factors in curatively resected pathological stage I lung adenocarcinoma[J]. J Thorac Dis, 2017, 9(12): 5267-5277.
|
| 6 |
Zhao W, Wang H, Xie J, et al. A clinicopathological study of small lung adenocarcinoma 1 cm or less in size: Emphasis on histological subtypes associated with lymph node metastasis and recurrence[J]. Int J Surg Pathol, 2018, 26(1): 4-11.
|
| 7 |
Neri S, Menju T, Sowa T, et al. Prognostic impact of microscopic vessel invasion and visceral pleural invasion and their correlations with epithelial-mesenchymal transition, cancer stemness, and treatment failure in lung adenocarcinoma[J]. Lung Cancer, 2019, 128: 13-19.
|
| 8 |
Chae M, Jeon JH, Chung JH, et al. Prognostic significance of tumor spread through air spaces in patients with stage ⅠA part-solid lung adenocarcinoma after sublobar resection[J]. Lung Cancer, 2021, 152: 21-26.
|
| 9 |
Han YB, Kim H, Mino-Kenudson M, et al. Tumor spread through air spaces (STAS): prognostic significance of grading in non-small cell lung cancer[J]. Mod Pathol, 2021, 34(3): 549-561.
|
| 10 |
Vaghjiani RG, Takahashi Y, Eguchi T, et al. Tumor spread through air spaces is a predictor of occult lymph node metastasis in clinical stage ⅠA lung adenocarcinoma[J]. J Thorac Oncol, 2020, 15(5): 792-802.
|
| 11 |
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.[J]. N Engl JMed, 2010, 362(25): 2380-2388.
|
| 12 |
Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
|
| 13 |
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): v192-v237.
|
| 14 |
Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy[J]. Ann Oncol, 2021, 32(12): 1637-1642.
|
| 15 |
沈 晨，方文涛. ⅠA期肺腺癌病理高危因素及术后辅助化疗研究进展[J]. 中国肺癌杂志，2022, 25(8): 593-600.
|
| 16 |
Yun JK, Lee GD, Choi S, et al. Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection[J]. Transl Lung Cancer Res, 2022, 11(7): 1327-1336.
|
| 17 |
Ito M, Miyata Y, Kushitani K, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma[J]. Thorac Cancer, 2018, 9(12): 1594-1602.
|
| 18 |
He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial[J]. Lancet Respir Med, 2021, 9(9): 1021-1029.
|
| 19 |
Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respir Med, 2018, 6(11): 863-873.
|
| 20 |
Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018, 19(1): 139-148.
|
| 21 |
Tsuboi M, Wu Y, Grohe C, et al. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage ⅠB-ⅢIA non-small cell lung cancer (NSCLC): Updated results from ADAURA[J]. Ann Oncol, 2022, 33: S1413-S1414.
|
| 22 |
Saw SPL, Lai G, Zhou S, et al. OA06.05 Molecular and clinical features associated with relapse in early stage EGFR-Mutated NSCLC: A single institution knowledge bank[J]. J Thoracic Oncol, 2021, 16(3, Supplement): S114-S115.
|
| 23 |
Garinet S, Wang P, Mansuet-Lupo A, et al. Updated prognostic factors in localized NSCLC[J]. Cancers (Basel), 2022, 14(6): 1400.
|
| 24 |
Masago K, Kuroda H, Fujita S, et al. Biological difference between L858R and exon 19 deletion contributes to recurrence-free survival of resected non-small cell lung cancer[J]. Oncology, 2022, doi: 10.1159/000526973.
|
| 25 |
Hedley BD, Chambers AF. Tumor dormancy and metastasis[J]. Adv Cancer Res, 2009, 102: 67-101.
|
| 26 |
Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis[J]. Thorax, 2010, 65(3): 241-245.
|
| 27 |
Moreira AL, Ocampo P, Xia Y, et al. A grading system for invasive pulmonary adenocarcinoma: A proposal from the international association for the study of lung cancer pathology committee[J]. J Thorac Oncol, 2020, 15(10): 1599-1610.
|
| 28 |
Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: Impact of advances since 2015[J]. J Thorac Oncol, 2022, 17(3): 362-387.
|
| 29 |
Kim M, Chung YS, Kim KA, et al. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung[J]. Lung Cancer, 2019, 137: 129-135.
|
| 30 |
Lin C, Hu F, Chu H, et al. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis[J]. Thorac Cancer, 2021, 12(7): 1084-1095.
|
| 31 |
Tada H, Mitsudomi T, Misumi T, et al. Randomized phase Ⅲ study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage Ⅱ-ⅢA non-small-cell lung cancer with EGFR mutation (IMPACT)[J]. J Clin Oncol, 2022, 40(3): 231-241.
|
| 32 |
蒋仲敏，林殿杰，叶 莘，等. 循环肿瘤细胞、循环染色体异常细胞与肺癌早期诊断[J]. 精准医学杂志，2020, 35(2): 95-99.
|